dengu
viru
denv
signific
arbovir
infect
human
estim
million
infect
million
symptomat
case
annual
denv
complex
consist
four
distinct
serotyp
infect
one
serotyp
induc
longterm
protect
immun
homolog
serotyp
fact
immun
one
serotyp
associ
increas
risk
sever
diseas
upon
subsequ
infect
differ
serotyp
confound
factor
vaccin
design
mani
dengu
vaccin
clinic
trial
tetraval
liveattenu
viru
formul
design
simultan
induc
protect
immun
serotyp
howev
phase
efficaci
trial
asia
latin
america
lead
vaccin
efficaci
serotyp
efficaci
serotyp
moreov
vaccine
less
year
age
incid
hospit
virolog
confirm
dengu
higher
seen
match
nonvaccin
control
demonstr
critic
need
new
metric
protect
immun
describ
main
site
recogn
typespecif
durabl
neutral
antibodi
peopl
primat
expos
natur
infect
candid
live
attenu
vaccin
denv
envelop
e
glycoprotein
main
target
protect
antibodi
e
protein
compos
three
domain
ii
iii
design
edi
edii
ediii
respect
denv
particl
monom
e
organ
dimer
cover
entir
surfac
viru
array
e
protein
arrang
icosahedr
symmetri
asymmetr
unit
contain
three
e
protein
dimer
human
monoclon
antibodi
hmab
neutral
denv
bind
quaternari
structur
epitop
requir
assembl
e
protein
homodim
higherord
structur
follow
infect
vaccin
denvspecif
serum
polyclon
antibodi
respons
respons
protect
principl
target
human
polyclon
antibodi
respons
neutral
denv
remain
elus
recent
describ
hmab
strongli
neutral
antibodi
isol
person
expos
primari
infect
studi
also
demonstr
recogn
complex
quaternari
epitop
display
intact
viru
recombin
e
protein
point
mutat
amino
acid
posit
ediii
residu
highlight
magenta
fig
b
led
complet
escap
neutral
indic
epitop
includ
ediii
residu
recent
fibriansah
et
al
solv
structur
bound
demonstr
antibodi
bound
quaternari
epitop
form
ediii
edii
two
differ
monom
within
singl
dimer
mab
power
tool
epitop
map
polyclon
serum
antibodi
respons
deriv
longliv
plasma
cell
protect
peopl
demonstr
defin
new
class
quaternari
epitop
main
target
serum
neutral
antibodi
peopl
expos
infect
lead
live
attenu
vaccin
candid
understand
role
ediii
epitop
neutral
antibodi
gener
design
recov
recombin
chimer
viru
entir
ediii
region
insert
backbon
sequenc
molecular
clone
creat
recombin
viru
design
see
fig
supplement
materi
recombin
viru
amino
acid
chang
ediii
compar
parent
wildtyp
wt
strain
fig
see
tabl
supplement
materi
grew
similar
level
wt
virus
insect
cell
human
monocyt
cell
line
express
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
known
dengu
receptor
partial
growth
impair
vero
cell
fig
denv
assembl
insid
cell
immatur
virion
contain
premembran
protein
prm
cleav
golgi
apparatu
result
format
matur
virion
proteolyt
cleavag
prm
ineffici
popul
virion
releas
infect
cell
admixtur
display
differ
stage
matur
matur
state
denv
may
influenc
display
epitop
sensit
antibodi
neutral
immunoblot
perform
compar
matur
state
chimera
wt
parent
strain
cell
particl
high
level
prm
particl
low
level
prm
rel
e
protein
indic
virion
matur
fig
chimera
matur
state
similar
indic
insert
ediii
serotyp
minim
alter
matur
state
backbon
serotyp
viru
fig
evalu
impact
ediii
exchang
overal
e
protein
topolog
virion
structur
probe
chimera
panel
epitopemap
human
mous
monoclon
antibodi
see
tabl
supplement
materi
denv
crossreact
mab
bound
chimera
indic
preserv
crossreact
epitop
fig
engag
serotypespecif
epitop
ediii
respect
fig
c
see
tabl
conson
recombin
viru
design
bound
neutral
chimera
wherea
fail
bind
neutral
chimera
fig
g
bind
neutral
nonhuman
primat
serotypespecif
mab
edi
epitop
disrupt
show
affect
neutral
epitop
present
domain
fig
h
see
tabl
overal
result
demonstr
chimera
display
epitop
manner
consist
display
properli
fold
function
chimer
e
protein
transplant
ediii
also
restor
bind
neutral
mab
even
though
antibodi
bind
recombin
ediii
alon
fig
see
tabl
predict
full
epitop
requir
antibodi
bind
neutral
includ
ediii
well
conserv
residu
adjac
domain
residu
ediii
alon
determin
specif
inde
cryoelectron
microscopi
structur
bound
demonstr
epitop
consist
residu
ediii
edii
differ
monom
within
singl
dimer
fusion
loop
region
edii
highli
conserv
across
denv
flavivirus
well
predict
variabl
ediii
dictat
typespecif
eight
contact
residu
identifi
ediii
five
differ
suggest
critic
residu
import
bind
neutral
natur
primari
infect
caus
longliv
serotypespecif
neutral
antibodi
respons
detect
decad
exposur
determin
epitop
creat
ediii
transplant
main
target
antibodi
neutral
assay
perform
wellcharacter
human
rhesu
macaqu
dengu
immun
sera
see
tabl
supplement
materi
parent
virus
expect
primari
immun
sera
strongli
neutral
fig
remark
major
case
sera
also
effici
neutral
viru
level
similar
measur
indic
ediii
replac
suffici
recreat
major
neutral
epitop
recogn
sera
viru
remain
fulli
sensit
neutral
immun
sera
fig
data
suggest
typespecif
neutral
antibodi
target
differ
epitop
e
protein
preserv
chimera
determin
neutral
specif
immun
sera
reflect
global
increas
sensit
neutral
dengu
immun
serum
panel
primari
immun
sera
test
three
virus
viru
display
increas
sensit
neutral
immun
sera
p
p
respect
demonstr
chimer
viru
global
sensit
antibodi
neutral
fig
determin
neutral
epitop
recogn
antibodi
immun
sera
entir
contain
within
transplant
ediii
includ
residu
ediii
adjac
domain
human
immun
sera
deplet
antibodi
bind
intact
virion
recombin
ediii
fig
b
test
abil
neutral
viru
see
fig
supplement
materi
previous
demonstr
recombin
ediii
protein
properli
fold
contain
welldefin
epitop
later
ridg
astrand
epitop
recogn
mous
human
neutral
antibodi
six
primari
human
immun
sera
deplet
use
virion
onehalf
threequart
neutral
potenc
lost
depend
serum
sampl
tabl
sera
deplet
use
rediii
alon
five
sera
display
minor
loss
neutral
one
sampl
lost
neutral
significantli
smaller
loss
neutral
deplet
tabl
p
result
indic
epitop
target
polyclon
typespecif
human
neutral
antibodi
requir
assembl
higherord
structur
simpl
domain
monom
e
protein
conclud
ediiicontain
quaternari
epitop
major
target
serotyp
longliv
polyclon
neutral
antibodi
develop
infect
determin
dengu
vaccin
induc
quaternari
epitopetarget
neutral
antibodi
test
sera
subject
develop
neutral
antibodi
receiv
monoval
live
attenu
vaccin
develop
nih
vaccin
sera
neutral
chimera
demonstr
vaccin
induc
neutral
antibodi
track
transplant
ediii
fig
p
determin
vaccineinduc
antibodi
also
recogn
quaternari
epitop
extend
beyond
ediii
three
vaccin
sera
deplet
antibodi
bind
intact
virion
recombin
ediii
test
abil
neutral
chimer
viru
three
sampl
deplet
whole
viru
led
nearli
complet
loss
neutral
antibodi
tabl
remov
ediiispecif
antibodi
result
loss
neutral
antibodi
one
vaccin
sampl
two
sampl
retain
major
neutral
antibodi
ediii
deplet
tabl
thu
vaccin
induc
neutral
antibodi
bind
epitop
contain
within
ediii
complex
epitop
extend
beyond
ediii
describ
approach
use
wholedomain
replac
identifi
princip
antigen
site
target
polyclon
antibodi
follow
natur
denv
infect
experiment
live
attenu
denv
vaccin
chimera
observ
clear
gain
neutral
loss
sensit
neutral
sera
suggest
princip
neutral
epitop
distinct
epitop
importantli
data
demonstr
singl
recombin
denv
design
encod
major
neutral
epitop
two
viru
serotyp
sever
recent
studi
point
import
quaternari
epitop
target
human
denv
neutral
antibodi
neutral
hmab
recogn
distinct
quaternari
structur
epitop
center
ediii
hing
howev
small
fraction
denvspecif
memori
bcell
clone
produc
strongli
neutral
antibodi
clear
epitop
defin
use
human
mab
main
target
polyclon
serum
neutral
antibodi
respons
well
studi
demonstr
serotypespecif
epitop
target
human
mab
polyclon
immun
sera
close
relat
ident
epitop
complex
quaternari
epitop
includ
critic
residu
ediii
determin
serotyp
specif
result
reveal
fundament
import
complex
quaternari
structur
surfac
denv
particl
drive
potent
antibodi
immun
respons
result
entir
consist
epitop
structur
report
fibriansah
et
al
antibodi
footprint
contain
critic
contact
residu
ediii
one
monom
well
fusion
loop
bc
loop
edii
adjac
monom
bridg
across
dimer
structur
also
demonstr
antibodi
contact
site
ediii
conserv
serotyp
contact
site
edii
highli
conserv
thu
serotyp
specif
determin
ediii
transplant
domain
suffici
creat
complet
function
epitop
dengu
vaccin
challeng
develop
need
formul
vaccin
four
compon
simultan
induc
durabl
neutral
protect
antibodi
serotyp
current
lead
dengu
tetraval
vaccin
result
increas
hospit
children
year
age
urgent
need
refin
metric
epitopespecif
neutral
respons
without
know
ident
critic
epitop
region
virus
four
serotyp
target
neutral
protect
polyclon
serum
antibodi
difficult
dissect
tetraval
vaccin
respons
efficaci
data
ongo
clinic
trial
epitopeexchang
norovirus
use
deciph
complex
polyclon
respons
pattern
vaccin
sampl
possibl
techniqu
use
dengu
tetraval
vaccin
sera
result
demonstr
nih
monoval
live
attenu
vaccin
induc
neutral
antibodi
similar
induc
natur
infect
chimera
power
tool
evalu
antibodi
sitespecif
respons
follow
infect
vaccin
trial
recombin
denv
express
quaternari
neutral
antibodi
epitop
serotyp
may
lead
simpler
effect
vaccin
current
tetraval
formul
recombin
virus
construct
use
fourcdna
clone
strategi
strategi
use
creat
wt
denv
infecti
clone
see
fig
supplement
materi
pattern
coronaviru
cdna
clone
genom
subclon
four
separ
cdna
plasmid
promot
introduc
end
fragment
uniqu
type
ii
restrict
endonucleas
cleavag
site
introduc
end
fragment
allow
systemat
assembl
genomelength
cdna
fulllength
transcript
deriv
ediii
residu
introduc
subclon
replac
e
nucleotid
correspond
nucleotid
encod
variant
amino
acid
new
fragment
nucleotid
synthes
insert
plasmid
biobas
new
plasmid
b
c
plasmid
grown
escherichia
coli
cell
purifi
digest
correspond
type
ii
restrict
enzym
ligat
use
dna
ligas
creat
fulllength
cdna
dengu
viral
genom
fulllength
cdna
transcrib
genomelength
rna
use
polymeras
previous
describ
group
recombin
rna
electropor
cell
cell
cultur
supernat
contain
viabl
viru
harvest
viru
passag
two
time
cell
centrifug
remov
cellular
debri
store
passag
repres
work
stock
mosquito
aed
albopictu
cell
grown
gibco
minim
essenti
medium
mem
cell
maintain
dulbecco
modifi
eagl
medium
dmem
dcsignexpress
cell
cell
maintain
rpmi
medium
supplement
fetal
bovin
serum
fb
cell
lower
infect
media
supplement
nonessenti
amino
acid
medium
also
supplement
lglutamin
media
addit
supplement
uml
penicillin
streptomycin
cell
incub
previous
describ
group
total
rna
isol
viral
supernat
use
templat
cdna
synthesi
use
standard
molecular
techniqu
serotypespecif
pcr
restrict
fragment
length
polymorph
rflp
restrict
endonucleas
analys
perform
cdna
sampl
order
valid
puriti
recombin
viral
prepar
see
fig
b
c
supplement
materi
equal
quantiti
viru
previous
titrat
enzymelink
immunosorb
assay
elisa
captur
use
either
mous
antidenv
mab
human
mab
primari
antibodi
dilut
start
concentr
rang
alkalin
phosphataseconjug
secondari
antibodi
use
detect
bind
primari
antibodi
pnitrophenyl
phosphat
substrat
reaction
color
chang
quantifi
spectrophotometri
previous
describ
deidentifi
human
denv
immun
sera
collect
individu
confirm
previou
natur
denv
infect
see
tabl
supplement
materi
donat
collect
complianc
institut
review
board
univers
north
carolina
chapel
hill
protocol
deidentifi
human
immun
sera
previous
collect
adult
given
nih
monoval
vaccin
clinicaltrialsgov
identifi
provid
anna
durbin
stephen
whitehead
sera
collect
follow
inform
consent
approv
western
institut
review
board
nonhuman
primat
immun
sera
collect
follow
experiment
denv
infect
kindli
provid
carlo
sariol
see
tabl
procedur
review
approv
institut
anim
care
use
committe
medic
scienc
campu
univers
puerto
rico
iacucuprmsc
perform
facil
accredit
associ
assess
accredit
laboratori
anim
care
aaalac
anim
welfar
assur
protocol
one
day
prior
inocul
cell
cultur
plate
seed
either
cell
cell
prior
inocul
growth
medium
remov
viru
titrat
perform
serial
dilut
viru
stock
incub
h
incub
viru
dilut
ad
cell
h
overlaid
ml
methylcellulos
optimem
gibco
supplement
fb
uml
penicillin
streptomycin
day
incub
overlay
remov
cell
wash
phosphatebuff
salin
pb
fix
methanol
plate
block
instant
milk
made
pb
incub
anti
mab
antiprm
mab
dilut
block
buffer
plate
wash
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
antibodi
sigma
dilut
block
buffer
plate
wash
foci
develop
trueblu
hrp
substrat
kpl
foci
count
focu
reduct
neutral
test
frnt
either
mab
sera
dilut
mix
focusform
unit
ffu
viru
incub
h
incub
viru
mab
serum
dilut
ad
cell
h
overlay
ad
process
describ
either
vero
cell
inocul
multipl
infect
moi
everi
h
cultur
supernat
harvest
centrifug
remov
cellular
debri
sampl
frozen
use
fresh
medium
replac
day
viru
titer
determin
propag
cell
type
describ
cell
infect
initi
infect
everi
h
sampl
cell
harvest
fix
permeabil
probe
antiprm
antibodi
conjug
alexa
fluor
infect
cell
quantifi
use
guava
flow
cytomet
millipor
viru
stock
dilut
pb
mix
laemmli
sampl
buffer
biorad
heat
min
sampl
run
protean
tgx
gel
biorad
transfer
polyvinyliden
difluorid
pvdf
membran
block
instant
milk
pb
plu
tween
overnight
membran
probe
anti
mab
antiprm
mab
mab
block
buffer
h
wash
hrpconjug
antimous
antihuman
secondari
antibodi
dilut
block
buffer
incub
h
room
temperatur
membran
expos
chemiluminesc
substrat
develop
film
polyclon
immun
sera
deplet
antibodi
previous
describ
briefli
polystyren
microspher
polysci
catalog
coat
purifi
antigen
microbix
catalog
bovin
serum
albumin
bsa
control
immun
sera
deplet
antibodi
incub
coat
bead
min
least
three
round
maximum
deplet
antibodi
measur
deplet
antibodi
confirm
elisa
polyclon
immun
sera
deplet
rediiibind
antibodi
previous
describ
rebind
antibodi
briefli
dynabead
life
technolog
catalog
coval
conjug
rediii
protein
follow
manufactur
protocol
bsa
control
immun
sera
deplet
antibodi
incub
conjug
bead
min
least
three
round
maximum
deplet
antibodi
measur
deplet
antibodi
confirm
elisa
elisa
plate
coat
directli
either
ng
antigen
ng
rediii
per
well
overnight
plate
block
describ
undeplet
control
deplet
antigenrediiideplet
sera
dilut
block
buffer
incub
plate
h
rediii
reactiv
antibodi
detect
use
secondari
antibodi
substrat
describ
